CRS and NE characteristics (N = 127)
| Grade* . | n (%)† . | Median (range) . | n (%)‡ . | |||||
|---|---|---|---|---|---|---|---|---|
| CRS onset, d . | CRS resolution, d . | NE onset, d . | NE resolution, d . | CRS onset before NE . | NE onset before CRS . | Same onset . | ||
| CRS only | ||||||||
| Any | 47 (37.0) | 5.0 (1.0-14.0) | 9.0 (2.0-17.0) | — | — | — | — | — |
| 1 | 33 (26.0) | 5.0 (2.0-14.0) | 8.0 (2.0-17.0) | — | — | — | — | — |
| 2 | 13 (10.2) | 5.0 (1.0-9.0) | 9.0 (6.0-15.0) | — | — | — | — | — |
| ≥3 | 1 (0.8) | 3.0 (3.0-3.0) | 8.0 (8.0-8.0) | — | — | — | — | — |
| NE only | ||||||||
| Any | 14 (11.0) | — | — | 10.0 (2.0-34.0) | 20.0 (7.0-94.0) | — | — | — |
| 1 | 4 (3.1) | — | — | 12.5 (8.0-20.0) | 23.5 (18.0-32.0) | — | — | — |
| 2 | 3 (2.4) | — | — | 17.0 (14.0-20.0) | 20.0 (20.0-20.0) | — | — | — |
| ≥3 | 7 (5.5) | — | — | 8.0 (2.0-34.0) | 19.0 (7.0-94.0) | — | — | — |
| Nonconcurrent CRS and NE | ||||||||
| Any | 21 (16.5) | 4.0 (1.0-11.0) | 9.0 (2.0-19.0) | 13.0 (6.0-66.0) | 25.0 (6.0-92.0) | 21 (100.0) | 0 | 0 |
| CRS and NE ≤2 | 16 (12.6) | 3.0 (1.0-7.0) | 9.0 (2.0-19.0) | 14.5 (6.0-66.0) | 27.5 (6.0-92.0) | 16 (100.0) | 0 | 0 |
| CRS or NE ≥3 | 5 (3.9) | 6.0 (3.0-11.0) | 12.0 (8.0-13.0) | 13.0 (9.0-15.0) | 23.0 (22.0-55.0) | 5 (100.0) | 0 | 0 |
| Concurrent CRS and NE | ||||||||
| Any | 45 (35.4) | 4.0 (1.0-12.0) | 10.0 (3.0-24.0) | 7.0 (1.0-18.0) | 16.0 (3.0-90.0) | 31 (68.9) | 8 (17.8) | 6 (13.3) |
| CRS and NE ≤2 | 29 (22.8) | 5.0 (2.0-8.0) | 10.0 (3.0-24.0) | 7.0 (1.0-16.0) | 14.0 (3.0-42.0) | 20 (69.0) | 6 (20.7) | 3 (10.3) |
| CRS or NE ≥3 | 12 (9.4) | 4.0 (1.0-12.0) | 11.5 (6.0-23.0) | 8.0 (1.0-18.0) | 18.0 (12.0-90.0) | 8 (66.7) | 2 (16.7) | 2 (16.7) |
| CRS and NE ≥3 | 4 (3.1) | 4.0 (3.0-8.0) | 12.5 (9.0-16.0) | 5.5 (4.0-12.0) | 12.5 (25.0-30.0) | 3 (75.0) | 0 | 1 (25.0) |
| Any CRS | 113 | 5.0 (1.0-14.0) | 9.0 (2.0-24.0) | — | — | — | — | — |
| Any NE | 80 | — | 9.0 (1.0-66.0) | 19.0 (3.0-94.0) | — | — | — | |
| Grade* . | n (%)† . | Median (range) . | n (%)‡ . | |||||
|---|---|---|---|---|---|---|---|---|
| CRS onset, d . | CRS resolution, d . | NE onset, d . | NE resolution, d . | CRS onset before NE . | NE onset before CRS . | Same onset . | ||
| CRS only | ||||||||
| Any | 47 (37.0) | 5.0 (1.0-14.0) | 9.0 (2.0-17.0) | — | — | — | — | — |
| 1 | 33 (26.0) | 5.0 (2.0-14.0) | 8.0 (2.0-17.0) | — | — | — | — | — |
| 2 | 13 (10.2) | 5.0 (1.0-9.0) | 9.0 (6.0-15.0) | — | — | — | — | — |
| ≥3 | 1 (0.8) | 3.0 (3.0-3.0) | 8.0 (8.0-8.0) | — | — | — | — | — |
| NE only | ||||||||
| Any | 14 (11.0) | — | — | 10.0 (2.0-34.0) | 20.0 (7.0-94.0) | — | — | — |
| 1 | 4 (3.1) | — | — | 12.5 (8.0-20.0) | 23.5 (18.0-32.0) | — | — | — |
| 2 | 3 (2.4) | — | — | 17.0 (14.0-20.0) | 20.0 (20.0-20.0) | — | — | — |
| ≥3 | 7 (5.5) | — | — | 8.0 (2.0-34.0) | 19.0 (7.0-94.0) | — | — | — |
| Nonconcurrent CRS and NE | ||||||||
| Any | 21 (16.5) | 4.0 (1.0-11.0) | 9.0 (2.0-19.0) | 13.0 (6.0-66.0) | 25.0 (6.0-92.0) | 21 (100.0) | 0 | 0 |
| CRS and NE ≤2 | 16 (12.6) | 3.0 (1.0-7.0) | 9.0 (2.0-19.0) | 14.5 (6.0-66.0) | 27.5 (6.0-92.0) | 16 (100.0) | 0 | 0 |
| CRS or NE ≥3 | 5 (3.9) | 6.0 (3.0-11.0) | 12.0 (8.0-13.0) | 13.0 (9.0-15.0) | 23.0 (22.0-55.0) | 5 (100.0) | 0 | 0 |
| Concurrent CRS and NE | ||||||||
| Any | 45 (35.4) | 4.0 (1.0-12.0) | 10.0 (3.0-24.0) | 7.0 (1.0-18.0) | 16.0 (3.0-90.0) | 31 (68.9) | 8 (17.8) | 6 (13.3) |
| CRS and NE ≤2 | 29 (22.8) | 5.0 (2.0-8.0) | 10.0 (3.0-24.0) | 7.0 (1.0-16.0) | 14.0 (3.0-42.0) | 20 (69.0) | 6 (20.7) | 3 (10.3) |
| CRS or NE ≥3 | 12 (9.4) | 4.0 (1.0-12.0) | 11.5 (6.0-23.0) | 8.0 (1.0-18.0) | 18.0 (12.0-90.0) | 8 (66.7) | 2 (16.7) | 2 (16.7) |
| CRS and NE ≥3 | 4 (3.1) | 4.0 (3.0-8.0) | 12.5 (9.0-16.0) | 5.5 (4.0-12.0) | 12.5 (25.0-30.0) | 3 (75.0) | 0 | 1 (25.0) |
| Any CRS | 113 | 5.0 (1.0-14.0) | 9.0 (2.0-24.0) | — | — | — | — | — |
| Any NE | 80 | — | 9.0 (1.0-66.0) | 19.0 (3.0-94.0) | — | — | — | |
Lee et al12 criteria were used to determine CRS toxicity grade, and National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03)17 were used to determine NE toxicity grade.
Percentages based on patients who experienced a CRS and/or NE episode.
Percentages calculated within each row.